奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688606 奥泰生物

已收盘 11-22 15:00:01

{"stockData":{"symbol":"688606","market":"SH","secType":"STK","nameCN":"奥泰生物","latestPrice":69.24,"timestamp":1732258801000,"preClose":72.02,"halted":0,"volume":419500,"delay":0,"floatShares":79280900,"shares":79280900,"eps":3.4881,"marketStatus":"已收盘","marketStatusCode":5,"change":-2.78,"latestTime":"11-22 15:00:01","open":72.02,"high":72.48,"low":69.18,"amount":29851600,"amplitude":0.0458,"askPrice":69.24,"askSize":20,"bidPrice":69.21,"bidSize":6,"shortable":0,"etf":0,"ttmEps":3.4881,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":72.02,"symbolType":"stock_kcb","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":79.22,"lowLimit":64.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":79280855,"pbRate":1.41,"roa":"--","roe":"5.12%","epsLYR":2.28,"committee":-0.254902,"marketValue":5489000000,"floatMarketCap":5489000000,"peRate":19.850348,"changeRate":-0.0386,"turnoverRate":0.0053,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-11-25。","afterMarket":{"amount":0,"volume":0,"close":69.24,"buyVolume":0,"sellVolume":0,"time":1732260839464,"indexStatus":"已收盘 11-22 15:30:00","preClose":72.02}},"requestUrl":"/m/hq/s/688606/wiki","defaultTab":"wiki","newsList":[{"id":"2485104657","title":"奥泰生物：第三季度营业收入为2.22亿元，同比增长28.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485104657","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485104657?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:06","pubTimestamp":1732151160,"startTime":"0","endTime":"0","summary":"奥泰生物2024年第三季度报告显示，公司整体业绩表现强劲。第三季度营业收入为2.22亿元，同比增长28.72%，归属于上市公司股东的净利润为7365万元，同比增长142.39%。主要财务指标均实现大幅增长，主要原因是公司营业收入增长带动营业毛利提升，以及其他收益、投资收益等增加。此外，公司前三季度研发投入为7150万元，同比下降20.28%，占营业收入的比例为11.57%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-11-21/doc-incwusvs4709037.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-11-21/doc-incwusvs4709037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688606"],"gpt_icon":0},{"id":"2482565205","title":"奥泰生物：奥泰生物的芬太尼检测类产品拥有多款产品形式，包括单一卡型产品和十四合一毒品联检产品等","url":"https://stock-news.laohu8.com/highlight/detail?id=2482565205","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482565205?lang=zh_cn&edition=full","pubTime":"2024-11-11 18:00","pubTimestamp":1731319238,"startTime":"0","endTime":"0","summary":"奥泰生物董秘：2024年上半年，奥泰生物在欧盟市场的销售占比为22%左右；其中自有品牌在欧盟市场中占比39%左右。自从欧盟新法规发布以来，奥泰生物持续在IVDR产品注册方面投入了较多的人员和较高的费用。截至2024年10月底，公司已累计取得IVDR认证产品236项，是同行业内拥有IVDR产品数量较多的企业之一。感谢您对奥泰生物的关注!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100023127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2482276985","title":"奥泰生物11月11日遭主力抛售646万元 环比增加1556.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482276985","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482276985?lang=zh_cn&edition=full","pubTime":"2024-11-11 15:21","pubTimestamp":1731309676,"startTime":"0","endTime":"0","summary":"11月11日, 奥泰生物股价涨2.78%，报收70.66元，成交金额3394万元，换手率0.61%，振幅4.31%，量比0.89。奥泰生物今日主力资金净流出646万元，上一交易日主力净流出39万元，今日环比增加1556.41%。|11月11日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|托普云农|9.28%|#|兆讯传媒|6.69%|#|杰创智能|5.49%|#|兆日科技|4.91%|#|东南电子|4.88%|#|上海合晶|4.86%|#|巨轮智能|4.71%|#|初灵信息|4.24%|#|易点天下|4.21%|#|银宝山新|4.11%|奥泰生物所在的医疗器械行业，今日主力净流入8906万元，行业排名44/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111153759abb53bee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111153759abb53bee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2481461751","title":"奥泰生物11月08日主力资金流出39万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2481461751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481461751?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:19","pubTimestamp":1731050353,"startTime":"0","endTime":"0","summary":"11月08日, 奥泰生物股价跌0.84%，报收68.75元，成交金额2974万元，换手率0.54%，振幅3.42%，量比0.66。奥泰生物今日主力资金净流出39万元，连续7日净流出，上一交易日主力净流出304万元，今日环比减少87.17%。近一年数据显示，该股主力连续7日净流出后，次日下跌概率为40.00%，平均跌幅为2.68%。该股近5个交易日下跌3.40%，主力资金累计净流出2215万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出2320万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108153759a2233cb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108153759a2233cb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2480322769","title":"奥泰生物11月04日主力资金流出689万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2480322769","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480322769?lang=zh_cn&edition=full","pubTime":"2024-11-04 15:19","pubTimestamp":1730704747,"startTime":"0","endTime":"0","summary":"11月04日, 奥泰生物股价跌0.11%，报收71.09元，成交金额5317万元，换手率0.94%，振幅3.11%，量比1.03。奥泰生物今日主力资金净流出689万元，连续3日净流出，上一交易日主力净流出444万元，今日环比增加55.18%。该股近5个交易日上涨3.25%，主力资金累计净流出2676万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入79万元，其中净流入天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104153401ab9d7cc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104153401ab9d7cc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2480818195","title":"奥泰生物海外核心市场遇变局，近六成产品或因新规重新注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2480818195","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480818195?lang=zh_cn&edition=full","pubTime":"2024-11-02 12:00","pubTimestamp":1730520001,"startTime":"0","endTime":"0","summary":"不过，在上市至今的年报中，奥泰生物仅在2022年披露其获得5项IVDR新法规下检测试剂产品注册，未再对外专项披露IVDR新法规下的产品注册动态。相较而言，欧盟对奥泰生物的重要性更大。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102120019a20d5041&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102120019a20d5041&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2480096975","title":"奥泰生物（688606）2024年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2480096975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480096975?lang=zh_cn&edition=full","pubTime":"2024-11-01 06:28","pubTimestamp":1730413739,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期奥泰生物发布2024年三季报。截至本报告期末，公司营业总收入6.18亿元，同比上升10.37%，归母净利润1.98亿元，同比上升94.48%。按单季度数据看，第三季度营业总收入2.22亿元，同比上升28.72%，第三季度归母净利润7364.7万元，同比上升142.39%。本报告期奥泰生物盈利能力上升，毛利率同比增幅16.38%，净利率同比增幅76.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100006091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0},{"id":"2480957310","title":"东吴证券：给予奥泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480957310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480957310?lang=zh_cn&edition=full","pubTime":"2024-11-01 06:20","pubTimestamp":1730413244,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对奥泰生物进行研究并发布了研究报告《2024三季报点评：小而美POCT龙头，经营情况持续向好》，本报告对奥泰生物给出买入评级，当前股价为71.25元。　　奥泰生物　　投资要点　　事件：2024年10月30日，公司发布2024年三季度报告。近年来，奥泰生物通过上游生物原料自给和技术平台的持续创新，有效降低生产成本，并推动新产品的快速迭代。该股最近90天内共有2家机构给出评级，买入评级2家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100005642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","688606"],"gpt_icon":0},{"id":"2479708010","title":"开源证券：给予奥泰生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479708010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479708010?lang=zh_cn&edition=full","pubTime":"2024-10-31 18:02","pubTimestamp":1730368942,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,司乐致近期对奥泰生物进行研究并发布了研究报告《公司信息更新报告：2024Q3利润继续大超预期，公司成长逻辑持续兑现》，本报告对奥泰生物给出买入评级，当前股价为71.25元。截至2024H1公司已实现自产并投入使用的生物原料种类超过300种，其中24项为国内首创原料。该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100037677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688606"],"gpt_icon":0},{"id":"2479145775","title":"10月31日奥泰生物涨5.90%，国泰江源优势精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2479145775","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479145775?lang=zh_cn&edition=full","pubTime":"2024-10-31 16:19","pubTimestamp":1730362758,"startTime":"0","endTime":"0","summary":"证券之星消息，10月31日奥泰生物涨5.90%，收盘报71.25元，换手率1.94%，成交量1.54万手，成交额1.09亿元。重仓奥泰生物的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为国泰江源优势精选混合A。国泰江源优势精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100031269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2479716317","title":"奥泰生物大幅上涨 获主力净流入229万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479716317","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479716317?lang=zh_cn&edition=full","pubTime":"2024-10-31 09:47","pubTimestamp":1730339223,"startTime":"0","endTime":"0","summary":"10月31日，奥泰生物股价大幅上涨，截至09点47分，奥泰生物上涨5.17%，报70.76元/股，突破70元整数关口，成交2603万元，换手率0.47%。资金动向截止发稿，奥泰生物获得主力净流入229万元，其中超大单流入282万元，大单流出53万元。主营业务及业绩奥泰生物公司主营业务为体外诊断试剂的研发、生产和销售。最新财报显示，今年三季报，奥泰生物实现营业收入6.18亿元，同比增长10.37%，净利润为1.98亿元，同比增长94.48%，基本每股收益为2.49元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031094709a1fe1fd6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031094709a1fe1fd6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2479758760","title":"图解奥泰生物三季报：第三季度单季净利润同比增142.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479758760","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479758760?lang=zh_cn&edition=full","pubTime":"2024-10-31 01:57","pubTimestamp":1730311032,"startTime":"0","endTime":"0","summary":"证券之星消息，奥泰生物2024年三季报显示，公司主营收入6.18亿元，同比上升10.37%；归母净利润1.98亿元，同比上升94.48%；扣非净利润1.54亿元，同比上升59.78%；其中2024年第三季度，公司单季度主营收入2.22亿元，同比上升28.72%；单季度归母净利润7364.7万元，同比上升142.39%；单季度扣非净利润6100.76万元，同比上升130.57%；负债率6.74%，投资收益1159.08万元，财务费用-1212.75万元，毛利率55.76%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100003019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0},{"id":"2479108575","title":"奥泰生物：2024Q3利润继续大超预期 公司成长逻辑持续兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2479108575","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479108575?lang=zh_cn&edition=full","pubTime":"2024-10-31 00:00","pubTimestamp":1730304000,"startTime":"0","endTime":"0","summary":"核心逻辑在于客户数量激增，自主品牌比例提升明显，新品研发上市节奏加快公司已上市产品多达 1300 余种，产品广泛应用于临床检测、现场检测等多个领域，能满足客户的多元化需求，并持续聚焦研发注册，2024H1 公司新增53 项产品上市，自主研发的十四合一毒品联检产品获得美国FDA510K 认证。截至2024H1 公司已实现自产并投入使用的生物原料种类超过 300 种，其中 24 项为国内首创原料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103120162695bd9b0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103120162695bd9b0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2479202051","title":"奥泰生物(688606.SH)发布前三季度业绩，净利润1.98亿元，同比增长94.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479202051","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479202051?lang=zh_cn&edition=full","pubTime":"2024-10-30 20:57","pubTimestamp":1730293067,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥泰生物(688606.SH)披露2024年第三季度报告，公司前三季度实现营收6.18亿元，同比增长10.37%;归母净利润1.98亿元，同比增长94.48%;扣非净利润1.54亿元，同比增长59.78%;基本每股收益2.49元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1204148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688606"],"gpt_icon":0},{"id":"2477765025","title":"奥泰生物大幅上涨 获主力净流入77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477765025","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477765025?lang=zh_cn&edition=full","pubTime":"2024-10-21 09:41","pubTimestamp":1729474916,"startTime":"0","endTime":"0","summary":"10月21日，奥泰生物股价大幅上涨，截至09点41分，奥泰生物上涨5.02%，报70.77元/股，突破70元整数关口，成交1031万元，换手率0.19%。资金动向截止发稿，奥泰生物获得主力净流入77万元，其中超大单流入69万元，大单流入8万元。主营业务及业绩奥泰生物公司主营业务为体外诊断试剂的研发、生产和销售。最新财报显示，今年中报，奥泰生物实现营业收入3.97亿元，同比增长2.23%，净利润为1.24亿元，同比增长74.03%，基本每股收益为1.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241021094323ab6b858a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241021094323ab6b858a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2476471744","title":"奥泰生物(688606.SH)半年度每股派1.5元 股权登记日为10月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2476471744","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476471744?lang=zh_cn&edition=full","pubTime":"2024-10-18 16:04","pubTimestamp":1729238694,"startTime":"0","endTime":"0","summary":"奥泰生物(688606.SH)发布公告，公司将实施2024年半年度权益分派实，每股...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/12.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/12.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2476425400","title":"奥泰生物大幅上涨 获主力净流入104万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2476425400","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476425400?lang=zh_cn&edition=full","pubTime":"2024-10-18 13:36","pubTimestamp":1729229774,"startTime":"0","endTime":"0","summary":"10月18日，奥泰生物股价大幅上涨，截至13点36分，奥泰生物上涨5.12%，报66.96元/股，成交2333万元，换手率0.45%，振幅6.17%。资金动向截止发稿，奥泰生物获得主力净流入104万元，其中超大单流入67万元，大单流入36万元。主营业务及业绩奥泰生物公司主营业务为体外诊断试剂的研发、生产和销售。最新财报显示，今年中报，奥泰生物实现营业收入3.97亿元，同比增长2.23%，净利润为1.24亿元，同比增长74.03%，基本每股收益为1.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018135418a1e19bbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018135418a1e19bbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2474184731","title":"奥泰生物大幅上涨 第90届CMEF将在深圳举办","url":"https://stock-news.laohu8.com/highlight/detail?id=2474184731","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474184731?lang=zh_cn&edition=full","pubTime":"2024-10-10 09:45","pubTimestamp":1728524704,"startTime":"0","endTime":"0","summary":"10月10日，奥泰生物股价大幅上涨，截至09点45分，奥泰生物上涨5.04%，报69.67元/股，成交1161万元，换手率0.22%，振幅4.66%。消息解读第90届中国国际医疗器械博览会将在深圳国际会展中心(宝安)举办。本届CMEF整体展览面积近20万平方米，近4000家品牌企业将携数万款产品集中亮相，预计吸引超12万名专业观众到场参观。资金动向截止发稿，奥泰生物获得主力净流入72万元，其中超大单流出57万元，大单流入129万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010095238ab690031&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010095238ab690031&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2474004260","title":"奥泰生物大跌5.10% 3家券商给予买入建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2474004260","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474004260?lang=zh_cn&edition=full","pubTime":"2024-10-09 09:30","pubTimestamp":1728437401,"startTime":"0","endTime":"0","summary":"10月09日，奥泰生物股价大幅下跌，截至09点30分，奥泰生物下跌5.10%，报68.99元/股，失守70元整数关口，成交74万元，换手率0.01%。此外，数据统计显示，近半年内3家券商给予买入建议。资金动向截止发稿，奥泰生物获得主力净流出63万元，其中超大单流出35万元，大单流出27万元。最新财报显示，今年中报，奥泰生物实现营业收入3.97亿元，同比增长2.23%，净利润为1.24亿元，同比增长74.03%，基本每股收益为1.56元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009134734a1df4be5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009134734a1df4be5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2471843382","title":"奥泰生物创4个月新高 获融资净买入210万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2471843382","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471843382?lang=zh_cn&edition=full","pubTime":"2024-09-30 10:57","pubTimestamp":1727665031,"startTime":"0","endTime":"0","summary":"09月30日，奥泰生物股价大幅上涨，截至10点57分，奥泰生物上涨5.17%，报63.88元/股，创近4个月新高，成交5100万元，换手率1.04%，振幅5.84%。资金动向截止发稿，奥泰生物获得主力净流入80万元，其中超大单流入332万元，大单流出251万元。融资融券方面，奥泰生物09月27日获得融资净买入210万元，当日该股融资余额为4130万元，当较前一日增加5.36%，实现3连增；该股融券余额为38万元，融券余量为0.60万股，比上日减少6.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930113322ab66fcc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930113322ab66fcc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-03-25","address":"浙江省杭州市钱塘区江干区经济技术开发区白杨街道银海街550号第3幢第4幢第5幢厂房","stockEarnings":[{"period":"1week","weight":0.0453},{"period":"1month","weight":0.0061},{"period":"3month","weight":0.4461},{"period":"6month","weight":0.2979},{"period":"1year","weight":-0.0127},{"period":"ytd","weight":0.0633}],"companyName":"杭州奥泰生物技术股份有限公司","boardCode":"AI0027","perCapita":"15124股","boardName":"医药制造业","registeredCapital":"7928万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":"　　杭州奥泰生物技术股份有限公司主营业务是体外诊断试剂的研发、生产和销售。公司主要产品为POCT快速诊断试剂,包括毒品及药物滥用检测、传染病检测、妇女健康检测、肿瘤检测以及心脏标志物检测等五大系列,产品种类、形态多样,覆盖面广,目前已上市产品多达1200余种,广泛应用于临床检测、现场检测及个人健康管理等领域,能满足客户的多元化需求。公司获评浙江省高新技术企业创新能力500强、2022-2023中国医疗器械50强、杭州市总部企业、杭州市制造业百强企业、杭州数字服务贸易百强企业、全国首批“千企百城”商标品牌价值提升行动企业等多项荣誉。","serverTime":1732307321289,"listedPrice":133.67,"stockholders":"5242人(较上一季度增加0.77%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥泰生物,688606,奥泰生物股票,奥泰生物股票老虎,奥泰生物股票老虎国际,奥泰生物行情,奥泰生物股票行情,奥泰生物股价,奥泰生物股市,奥泰生物股票价格,奥泰生物股票交易,奥泰生物股票购买,奥泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}